scholarly journals The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia

Respirology ◽  
2017 ◽  
Vol 22 (7) ◽  
pp. 1459-1472 ◽  
Author(s):  
Jyotika D. Prasad ◽  
Annabelle Mahar ◽  
Jane Bleasel ◽  
Samantha J. Ellis ◽  
Daniel C. Chambers ◽  
...  
Keyword(s):  
New Zealand ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Position Statement ◽  
Multidisciplinary Meeting

scholarly journals Benefits of a virtual interstitial lung disease multidisciplinary meeting in the face of COVID ‐19

Respirology ◽  
2021 ◽  
Author(s):  
John A. Mackintosh ◽  
Laura Glenn ◽  
Hayley Barnes ◽  
Emily Dunn ◽  
Sandra Bancroft ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Multidisciplinary Meeting ◽  
The Face

scholarly journals Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Irene Moore ◽  
◽  
Jeremy Wrobel ◽  
Jessica Rhodes ◽  
Qi Lin ◽  
...  
Keyword(s):  
New Zealand ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Best Practice ◽  
Epidemiological Data ◽  
National Registry ◽  
Second Phase ◽  
Pilot Phase ◽  
Treatment Pathways ◽  
Progressive Respiratory Failure

Abstract Background Interstitial Lung Disease (ILD) is a group of respiratory conditions affecting the lung interstitium often associated with progressive respiratory failure. There is increasing recognition of the need for improved epidemiological data to help determine best practice and improve standardisation of care. The Australasian ILD Registry (AILDR) is a bi-national registry of patients with all ILD subtypes designed to establish a clinically meaningful database reflecting real world practice in Australasia with an objective to improve diagnostic and treatment pathways through research and collaboration. Methods AILDR is a prospective observational registry recruiting patients attending ILD clinics at centres around Australia and New Zealand. Core and non-core data are stored on a secure server. The pilot phase was launched in 2016 consisting of four sites in Australia. Currently in its second phase a further 16 sites have been recruited, including three in New Zealand. Results A total of 1061 participants were consented during the pilot phase. Baseline data demonstrated a mean age 68.3 ± 12.5 (SD) years, mean FVC (%predicted) 79.1 ± 20.4 (SD), mean DLCO (%predicted) 58.5 ± 17.9 (SD) and nadir exertional SpO2 (%) 91 ± 6.9 (SD). Idiopathic pulmonary fibrosis (31%) and connective-tissue disease related ILD (21.7%) were the two most common subtypes. Baseline demographics and physiology were not significantly different across the four centres. Conclusion AILDR is an important clinical and research tool providing a platform for epidemiological data that will prove essential in promoting understanding of a rare cohort of lung disease and provide foundations for our aspiration to standardise investigation and treatment pathways of ILD across Australasia.

scholarly journals Australasian Interstitial Lung Disease Registry (AILDR): Objectives, Design and Rationale of a Bi-National Prospective Database

2020 ◽  
Author(s):  
Irene Moore ◽  
Jeremy Wrobel ◽  
Jessica Rhodes ◽  
Qi Lin ◽  
Susanne Webster ◽  
...  
Keyword(s):  
New Zealand ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Best Practice ◽  
Epidemiological Data ◽  
National Registry ◽  
Second Phase ◽  
Pilot Phase ◽  
Treatment Pathways ◽  
Progressive Respiratory Failure

Abstract Background: Interstitial Lung Disease (ILD) is a group of respiratory conditions affecting the lung interstitium often associated with progressive respiratory failure. There is increasing recognition of the need for improved epidemiological data to help determine best practice and improve standardisation of care. The Australasian ILD Registry (AILDR) is a bi-national registry of patients with all ILD subtypes designed to establish a clinically meaningful database reflecting real world practice in Australasia with an objective to improve diagnostic and treatment pathways through research and collaboration. Methods: AILDR is a prospective observational registry recruiting patients attending ILD clinics at centres around Australia and New Zealand. Core and non-core data are stored on a secure server. The pilot phase was launched in 2016 consisting of four sites in Australia. Currently in its second phase a further 16 sites have been recruited, including three in New Zealand. Results: A total of 1061 participants were consented during the pilot phase. Baseline data demonstrated a mean age 68.3 ± 12.5 (SD) years, mean FVC (%predicted) 79.1 ± 20.4 (SD), mean DLCO (%predicted) 58.5 ± 17.9 (SD) and nadir exertional SpO2 (%) 91 ± 6.9 (SD). Idiopathic pulmonary fibrosis (31%) and connective-tissue disease related ILD (21.7%) were the two most common subtypes. Baseline demographics and physiology were not significantly different across the four centres. Conclusion: AILDR is an important clinical and research tool providing a platform for epidemiological data that will prove essential in promoting understanding of a rare cohort of lung disease and provide foundations for our aspiration to standardise investigation and treatment pathways of ILD across Australasia.

scholarly journals Respiratory management of infants with chronic neonatal lung disease beyond the NICU : A position statement from the Thoracic Society of Australia and New Zealand*

Respirology ◽  
2020 ◽  
Vol 25 (8) ◽  
pp. 880-888 ◽  
Author(s):  
Nitin Kapur ◽  
Gillian Nixon ◽  
Philip Robinson ◽  
John Massie ◽  
Bernadette Prentice ◽  
...  
Keyword(s):  
New Zealand ◽  
Lung Disease ◽  
Position Statement ◽  
Respiratory Management ◽  
Neonatal Lung ◽  
Chronic Neonatal Lung Disease

Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement

2020 ◽  
Vol 4 (3) ◽  
pp. 147-155
Author(s):  
Jolene H. Fisher ◽  
Kerri A. Johannson ◽  
Deborah Assayag ◽  
Julie Morisset ◽  
Kaissa de Boer ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Position Statement ◽  
Long Term Monitoring ◽  
Term Monitoring

scholarly journals Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*

Respirology ◽  
2020 ◽  
Vol 25 (3) ◽  
pp. 321-335
Author(s):  
Jack Dummer ◽  
Claudia C. Dobler ◽  
Mark Holmes ◽  
Daniel Chambers ◽  
Ian A. Yang ◽  
...  
Keyword(s):  
New Zealand ◽  
Lung Disease ◽  
Position Statement ◽  
Diagnosis And Treatment ◽  
Antitrypsin Deficiency

Regarding the “Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement”

2018 ◽  
Vol 2 (3) ◽  
pp. 182-183
Author(s):  
Onofre Moran-Mendoza ◽  
Marco Mura ◽  
David McCormack ◽  
Venerino Poletti ◽  
Sara Tomassetti ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Position Statement
Sign in / Sign up

Export Citation Format

Share Document